Department of Pediatrics, Şişli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Department of Pediatric Endocrinology and Diabetes, Şişli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Horm Res Paediatr. 2021;94(9-10):343-352. doi: 10.1159/000521180. Epub 2021 Nov 26.
Spexin (SPX) is a novel peptide implicated in food intake and satiety. SPX levels are reduced in obese patients.
This study aimed to compare serum SPX levels in obese adolescents versus healthy controls and to assess the associations of metabolic syndrome (metS) antecedents with serum SPX levels.
Eighty consecutive obese adolescents aged 10-18 years and 80 healthy peers were enrolled. Anthropometric measurements, pubertal examinations, and clinical blood pressure measurements were performed. Fasting blood samples were drawn for glucose, insulin, lipids, uric acid, alanine aminotransferase (ALT), and SPX. metS was diagnosed using International Diabetes Federation criteria. Associations of serum SPX with clinical and laboratory variables were assessed.
Obese adolescents had lower serum SPX levels than healthy peers (50 pg/mL [25-75% IQR: 25-98 pg/mL] and 67.0 pg/mL [25-75% IQR: 32.5-126.0 pg/mL]; respectively, p = 0.035). Twenty (25%) obese adolescents were diagnosed as having metS. Obese adolescents with metS had lower SPX than those without metS (24.5 pg/mL [25-75% IQR: 15.3-49.5 pg/mL] and 69.0 pg/mL [25-75% IQR: 42.0-142.0 pg/mL]; respectively, p < 0.0001). The frequencies of hyperuricemia, IR, and elevated ALT were similar in obese adolescents with metS and those without metS (p > 0.05 for all). Serum uric acid levels were correlated significantly with serum SPX after correcting for BMI and HOMA-IR (r = -0.41, p < 0.05). A serum SPX level at a cutoff level of 49.5 pg/mL predicted the presence of metS in obese adolescents with 75% sensitivity and 71% specificity.
Obese adolescents have reduced SPX levels, and this reduction is more pronounced in those with metS. Further research is needed to verify the utility of SPX as a biomarker in the diagnosis of metS in obese adolescents.
Spexin（SPX）是一种新型肽，与摄食和饱腹感有关。肥胖患者的 SPX 水平降低。
本研究旨在比较肥胖青少年与健康对照者的血清 SPX 水平，并评估代谢综合征（metS）前体与血清 SPX 水平的关系。
连续纳入 80 例 10-18 岁肥胖青少年和 80 名健康同龄人。进行人体测量、青春期检查和临床血压测量。抽取空腹血样检测血糖、胰岛素、血脂、尿酸、丙氨酸氨基转移酶（ALT）和 SPX。采用国际糖尿病联合会标准诊断 metS。评估血清 SPX 与临床和实验室变量的关系。
肥胖青少年的血清 SPX 水平低于健康同龄人（50 pg/mL [25-75% IQR：25-98 pg/mL] 和 67.0 pg/mL [25-75% IQR：32.5-126.0 pg/mL]；分别为 p = 0.035）。20（25%）例肥胖青少年被诊断为患有 metS。患有 metS 的肥胖青少年的 SPX 水平低于无 metS 的肥胖青少年（24.5 pg/mL [25-75% IQR：15.3-49.5 pg/mL] 和 69.0 pg/mL [25-75% IQR：42.0-142.0 pg/mL]；分别为 p < 0.0001）。患有 metS 和无 metS 的肥胖青少年的高尿酸血症、IR 和 ALT 升高的频率相似（p > 0.05）。在校正 BMI 和 HOMA-IR 后，血清尿酸水平与血清 SPX 呈显著相关（r = -0.41，p < 0.05）。血清 SPX 水平在 49.5 pg/mL 截定点预测肥胖青少年存在 metS 的灵敏度为 75%，特异性为 71%。
肥胖青少年的 SPX 水平降低，在患有 metS 的肥胖青少年中更为明显。需要进一步研究来验证 SPX 作为肥胖青少年 metS 诊断的生物标志物的效用。
